News

Exciting Business Developments at Longevity Health Holdings

Exciting Business Developments at Longevity Health Holdings

Positive Updates from Longevity Health Holdings

Longevity Health Holdings, Inc. (Nasdaq: XAGE) is dedicated to enhancing human longevity through innovative technologies in regenerative bio-aesthetics, diagnostics, and nutrition. The company recently announced several key developments that indicate its commitment to growth and innovation.

Strategic Merger with 20/20 BioLabs

A major highlight for Longevity Health Holdings is the signed merger agreement with 20/20 BioLabs. Executed on April 11, 2025, this agreement will allow 20/20 to function as a wholly-owned subsidiary of XAGE once all closing conditions are met. This strategic move is anticipated to bolster their beneficial capabilities and services in the healthcare sector.

Details of the Merger

The filing of an S-4 prospectus with the Securities and Exchange Commission on May 8, 2025, marks an important step in this merger process. Integrating 20/20 BioLabs’ innovative laboratory tests will enhance XAGE's ability to provide cutting-edge solutions for chronic disease management and early detection of health issues.

Strong Sales Performance in Q1

Longevity Health Holdings has reported impressive sales figures for the first quarter, with XAGE achieving approximately $663,000, reflecting an 8% increase compared to the previous year. Not to be outdone, 20/20 reported sales reaching around $562,000, which is a 15% increase over the same timeframe. These results signify a positive market response to their products and services.

What This Means for Future Growth

Such growth in sales demonstrates the effectiveness of their products and services in meeting consumer needs in the realm of health and wellness. By focusing on both innovative solutions and customer satisfaction, XAGE is positioning itself for sustained future success.

Reverse Stock Split Details

Another significant update for shareholders is the completion of a reverse stock split at a ratio of 1 for 30, effective May 12, 2025. This strategic decision aims to increase the market price per share and improve the company's visibility in the investment community. Shares began trading at the adjusted price on May 14, 2025.

Exciting Product Launches Ahead

Looking forward, XAGE anticipates launching new products by the second quarter. Notably, they are set to introduce a medicated cleanser designed for use in medical offices and MedSpas, specifically targeting 20/20’s existing customer base, which includes many firefighters.

Innovative Lab Tests from 20/20

Moreover, 20/20 plans to unveil a revolutionary lab test that measures inflammatory biomarkers in blood—an essential factor linked to premature aging. This new product is expected to effectively cater to XAGE’s clientele, targeting physicians and medical spas.

New Partnerships and Initiatives

20/20 has also announced a notable partnership with Giant Food, initiating tests in nine stores across selected regions to offer their multi-cancer detection blood test, OneTest™. They are considering expanding into a test that identifies biomarkers associated with pro-inflammatory foods, further enriching their health solutions portfolio.

Future Financing Plans

In addition to these substantial operational updates, XAGE is actively exploring funding options and is expected to announce a primary investment initiative in the upcoming quarter. As they expand their capabilities, securing additional financing will be pivotal for supporting their innovative solutions.

About Longevity Health Holdings

Longevity Health Holdings is at the forefront of health science, focusing on trends in healthy aging and longevity. They aim to provide leading-edge products to help individuals feel their best at any age. Their offerings include state-of-the-art regenerative technologies such as the Carmell Secretome™ and Elevai Exosomes™. These advancements leverage the healing power of human platelets and mesenchymal stem cells, showcasing the company's dedication to innovative health solutions.

Frequently Asked Questions

What is the focus of Longevity Health Holdings?

Longevity Health Holdings specializes in extending human longevity and promoting healthy aging with innovative products in bio-aesthetics, diagnostics, and nutrition.

What are the major updates announced by XAGE recently?

The recent updates include a merger with 20/20 BioLabs, strong sales performance, a reverse stock split, anticipated product launches, and new partnerships.

How have sales numbers changed for XAGE and 20/20?

XAGE reported Q1 sales of approximately $663,000, up 8% year-over-year, while 20/20 saw sales of about $562,000, representing a 15% increase.

What is the significance of the recent reverse stock split?

The reverse stock split at a 1 for 30 ratio is intended to enhance the share price and strengthen the company's market position.

What new products are expected from XAGE and 20/20?

New products include a medicated cleanser for physicians and MedSpas, and a lab test measuring inflammatory biomarkers by 20/20.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading